Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
As Insmed prepares to unveil key data for its TPIP program at a major medical congress, fresh analyst coverage highlights the treatment's potential to reshape the company's future. Amidst a volatile stock performance, investors are weighing high-growth prospects against persistent financial risks.
Erik Prince, founder of the private military firm Blackwater, has filed to take his AI-powered drone autonomy company Swarmer Inc. public on Nasdaq. The firm's technology, extensively tested in Ukraine, highlights the accelerating shift toward software-defined warfare.
Private equity firm RoundTable Healthcare Partners has acquired the dermatologist-trusted skincare and sun protection brand Colorescience from 1315 Capital, as the company's annual sales approach the $100 million mark.
As Alphabet prepares to report its fourth-quarter results, investors are weighing the company's robust AI-driven growth against a stock that may have already priced in much of the good news.
Despite a star-studded client list and explosive revenue growth, IonQ's towering valuation and the nascent state of quantum computing signal significant risk for investors eyeing the recent sell-off.
Hyperliquid has upgraded its core engine with the HIP-4 protocol, introducing a novel 'Outcomes' contract system designed for prediction markets and structured products, currently in testnet phase.
President Trump's latest push to improve housing affordability centers on lowering borrowing costs, not home values. But with a severe shortage of homes and prices near record highs, economists warn his proposals may simply reignite price surges rather than create lasting relief for aspiring homeowners.
DaVita Inc. shares soared after the kidney care provider posted robust fourth-quarter results and issued a 2026 profit forecast that significantly exceeded Wall Street expectations, signaling resilience against cost pressures and past operational challenges.
As Wall Street remains fixated on software-based AI, a leading tech analyst argues the next trillion-dollar opportunity lies in 'physical AI'—machines that see, move, and act. Dan Ives of Wedbush singles out Tesla and Nvidia as the indispensable architects of this new industrial revolution.
As Alphabet prepares to report its fourth-quarter results, traders are bracing for significant stock movement. The focus is on whether strong performance in cloud and AI can justify its recent surge and sustain momentum amid heightened investor scrutiny.
As stock markets cool from years of stellar gains, a disciplined rebalancing is underway. Vanguard data reveals a broad-based move into fixed income, signaling a strategic pivot rather than panic.
Major U.S. stock indices advanced Monday, setting a positive tone for a week packed with corporate earnings reports from technology giants and other bellwethers. Investor sentiment remains cautiously optimistic as early results surpass expectations.
Investment firm Stanich Group has liquidated its entire position in the iShares ESG Aware USD Corporate Bond ETF (SUSC), a move analysts interpret as a reallocation towards equities amid shifting macroeconomic forecasts.
A new discounted cash flow analysis suggests Nine Entertainment Co. Holdings' shares could be trading at half their intrinsic value, sparking debate among investors about the true worth of the Australian media giant in a challenging advertising landscape.
Microsoft secures a major cloud agreement with AI search firm Perplexity, even as its stock faces pressure following a post-earnings selloff. The deal underscores Azure's growing appeal to AI startups, but questions linger over the tech giant's capacity constraints and investment priorities.
While many AI stocks trade at sky-high premiums, Nebius Group presents a contrasting case. Analysts project a staggering revenue surge for 2026, suggesting its current valuation might not fully reflect its growth trajectory in the competitive cloud AI space.
